ListarInstituto de Investigación Biomédica da Coruña (INIBIC) por tema "Safety"

Mostrando ítems 1-7 de 7

    • A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus 

      Vázquez Estévez, Sergio; Anido Herranz, Urbano; Lázaro Quintela, Martín; Fernández Calvo, Ovidio; Fernández-Núñez, Natalia; Dios Álvarez, N. de; Varela, V.; Campos Balea, B.; Agraso, S.; Areses, M. C.; Iglesias, L.; Blanco, Moisés; Maciá, S.; Antón-Aparicio, Luis M. (Springer, 2020-02-15)
      [Abstract] Background This article describes and compares approved targeted therapies and the newer immunotherapy agents. Materials and methods This article especially performs an in-depth review of currently available ...

    • Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma 

      Iglesias, Pedro; Biagetti, Betina; Araújo-Castro, Marta; Alcázar, Victoria; Guerrero-Pérez, Fernando; Rivero, Noelia; Casteràs, Anna; García Izquierdo, Belén; García Gómez, Carlos; Viedma Torres, Víctor; Pascual-Corrales, Eider; Pavón, Isabel; Villabona, Carles; Cordido, Fernando; Díez, Juan J. (Springer, 2022-11-10)
      [Abstract] Background: In recent years, dopamine agonists (DAs) have become an attractive therapeutic option to prevent both tumor growth and post-surgical tumor remnant growth in clinically non-functioning pituitary adenoma ...

    • Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION‐HEART multicentre randomised trial 

      Comín-Colet, Josep; Manito, Nicolás; Segovia-Cubero, Javier; Delgado Jiménez, Juan Francisco; García-Pinilla, José Manuel; Almenar, Luis; Crespo-Leiro, María Generosa; Sionis, Alessandro; Blasco, Teresa; Pascual Figal, Domingo A.; González-Vílchez, Francisco; Lambert Rodríguez, José Luis; Grau, María; Bruguera, Jordi (Wiley, 2018)
      [Abstract] Aims. The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan ...

    • Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies 

      Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós Fernández, Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aránzazu; Climent, Miguel Ángel; Arranz, José Ángel; Méndez, María José; Fernández Parra, Eva; Antón-Aparicio, Luis M.; Bayona, Cristina; Gallegos, Isabel; Gallardo, Enrique; Samaniego, Luz; García Donas, Jesús (Taylor & Francis, 2017-08-28)
      [Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ...

    • Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors 

      Pernas, Berta; Grandal, Marta; Tabernilla, Andrés; Cid-Silva, Purificación; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Mena, Álvaro; Margusino-Framiñán, Luis; Pedreira, José D.; Poveda, Eva (Wiley, 2016-06-06)
      [Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ...

    • Real-world effectiveness and safety of SDZ ETN, an etanercept biosimilar, in patients with rheumatic diseases: final results from multi-country COMPACT study 

      Schmalzing, Marc; Kellner, Herbert; Askari, Ayman; De-Toro, Javier; Vázquez Pérez-Coleman, Julio César; Foti, Rosario; Jeka, Slawomir; Haraoui, Boulos; Allanore, Yannick; Peichl, Peter; Oehri, Martin; Rahman, Masiur; Furlan, Fabricio; Romero, Elisa; Hachaichi, Sohaib; Both, Charlotte; Brueckmann, Ines; Sheeran, Tom (Springer Nature, 2023-11-11)
      [Abstract] Introduction: COMPACT, a non-interventional study, evaluated the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis ...

    • Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort 

      Rotea-Salvo, Sandra; Martínez-Pradeda, Alejandro; Fernández-Oliveira, Carla; Giménez-Arufe, Víctor; Balboa-Barreiro, Vanesa; Margusino-Framiñán, Luis; Mena-De-Cea, Álvaro; Vázquez-Rodríguez, Pilar; Castro-Iglesias, Ángeles; López-Calvo, Soledad; Martín-Herranz, Isabel; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2021-10-14)
      [Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients. Objectives: This study evaluated ...